SEC For	m 4																	
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person [*] Bryce Joanne						2. Issuer Name and Ticker or Trading Symbol Disc Medicine, Inc. [IRON]								neck all applie Directo	cable) or	10% Own		wner
(Last) (First) (Middle) C/O DISC MEDICINE, INC.					01/10/2024									Chief Financial Officer				specity
321 ARSENAL STREET, SUITE 101 (Street) WATERTOWN MA 02472					4.1	Line) X Form filed Form filed										oint/Group Filing (Check Applicable ed by One Reporting Person ed by More than One Reporting		
(City) (State) (Zip)					Person Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
1. Title of §	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature																	
			Date (Month/Day/Y		Year) if any (Month/Da			Code	nsaction Dispose le (Instr. 5)		Of (D) (Instr. 3, 4 and		Benefici Owned F Reported	ally Following	(D) o		of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) c (D)	Price	(instr. 3 and				
Common Stock 01/10						ve Securities Acquired,					18,16		\$0.(,			D	
				e.g., p	outs,	calls	s, warr	ants	s, optior	nsp ns, c	convertil	ble sec	urities)	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	Date,	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Ex Expiration (Month/Da	e	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e S Ily I	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisat		Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$63.9	01/10/2024			Α		27,250		(1)		01/09/2034	Common Stock	27,250	\$0.00	27,25	0	D	

Explanation of Responses:

1. 25% of the shares underlying this option shall vest and become exercisable on January 10, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

By: /s/ Rahul Khara, as Attorney-in-Fact

03/01/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.